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Abstract
Background: In standard reference sources, the incidence of coronary artery disease (CAD) in patients with atrial fibrillation
(AF) ranged between 24 and 46.5%. Since then, the incidence of cardiovascular risk factors (CRF) has increased and modern
treatment strategies (‘‘pill in the pocket’’) are only applicable to patients without structural heart disease. The aim of this
study was to investigate the incidence and severity of CAD in patients with AF.
Methods: From January 2005 until December 2009, we included 261 consecutive patients admitted to hospital with
paroxysmal, persistent or permanent AF in this prospective study. All patients underwent coronary angiography and the
Framingham risk score (FRS) was calculated. Patients with previously diagnosed or previously excluded CAD were
excluded.
Results: The overall incidence of CAD in patients presenting with AF was 34%; in patients .70 years, the incidence of CAD
was 41%. The incidence of patients undergoing a percutaneous coronary intervention (PCI) or coronary artery bypass graft
(CABG) was 21%. Patients with CAD were older (7368 years vs 68610 years, p=0.001), had significantly more frequent
hypercholesterolemia (60% vs 30%, p,0.001), were more frequent smokers (26% vs 13%, p=0.017) and suffered from
angina more often (37% vs 2%, p,0.001). There was a significant linear trend among the FRS categories in percentage and
the prevalence of CAD and PCI/CABG (p,0.0001).
Conclusions: The overall incidence of CAD in patients presenting with AF was relatively high at 34%; the incidence of PCI/
CABG was 21%. Based upon increasing CRF in the western world, we recommend a careful investigation respecting the FRS
to either definitely exclude or establish an early diagnosis of CAD – which could contribute to an early and safe therapeutic
strategy considering type Ic antiarrhythmics and oral anticoagulation.
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Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia,
affecting 2.3 million individuals in the USA and 4.5 million people
in the EU [1]. AF is associated with multiple symptoms, significant
mortality and morbidity and decreased quality of life [2,3].
Importantly, after acute myocardial infarction, development
of AF is associated with a worse prognosis [4]. Common
cardiovascular risk factors also give support to associate
coronary artery disease (CAD) and AF. Previous studies have
found that hypertension, diabetes and obesity are conditions
predisposing to AF [5], although in the case of diabetes
conflicting data have been reported [6]. The Framingham
study suggested that angina predisposed to AF and that the
association of AF with CAD was stronger in men [7]. Despite
the high prevalence of CAD in patients with AF of 18–46.5%
[8–12], the prevalence of AF among patients with proven CAD
is extremely low, at 0.2–5% [13–16]. By contrast, a survey of
historic literature by Zipes indicates that AF commonly occurs
in patients with CAD [17].
Over recent years, the incidence of cardiovascular risk factors of
the western world have dramatically increased and this trend is
projected to continue. Newer studies report different incidences of
CAD in patients with AF but also focus on different patient groups
[12,18], so data is lacking on the overall incidence of CAD in AF
patients in the modern era of cardiology. Further, the possibility of
specific antiarrhythmic therapy has increased the interest in
investigating patients with AF for CAD [19]. According to the
American Heart Association/American College of Cardiology
(AHA/ACC) guidelines, there is a class I recommendation for
flecainide and propafenone for pharmacological cardioversion and
a class IIa recommendation for flecainide and propafenone for
selected patients (‘‘pill-in-the-pocket’’) without structural heart
disease [20].
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24964The aim of the present study was to investigate invasively the
incidence and severity of CAD in patients with AF, presenting
without previously diagnosed or previously excluded CAD.
Methods
The study complies with the Declaration of Helsinki and all
patients gave written informed consent. This study was approved
by the Medical Ethic Commission II, Faculty of Medicine
Mannheim, University of Heidelberg. The study was also
performed in accordance with federal laws and regulations,
international accreditation standards and institutional policies.
Patient selection
From January 2005 until December 2009 we included 261
consecutive patients admitted to hospital with paroxysmal,
persistent or permanent AF in this prospective study. Independent
of the rhythm on admission, patients with previously known AF as
well as patients with diagnosed AF on admission were included.
Patients with previously diagnosed or previously excluded CAD,
acute coronary syndromes and dilated or hypertrophic cardiomy-
opathy were excluded.
All patients underwent coronary angiography and the Fra-
mingham risk score (FRS) was calculated. Type of AF (paroxys-
mal, permanent or persistent), baseline clinical data, cardiac risk
factors, left ventricular (LV) systolic function, existence of angina
pectoris, existence of hyperthyreosis, above-average alcohol
consumption and medication at discharge were (among others)
recorded. In patients diagnosed with CAD, the number of diseased
vessels and the affected coronary artery [left anterior descending
(LAD), left circumflex artery (LCX) and right coronary artery
(RCA)] were assessed. Diagnosis of CAD and indication for
percutaneous coronary intervention (PCI) was performed accord-
ing to the current AHA/ACC guidelines [21]. In patients
Figure 1. Significant linear trend among the FRS categories in
% and the prevalence of CAD and PCI/CABG (p,0.0001).
CABG=Coronary Artery Bypass Graft, CAD=Coronary Artery Disease,
FRS=Framingham Risk Score, PCI=Percutaneous Coronary Interven-
tion.
doi:10.1371/journal.pone.0024964.g001
Figure 2. Incidence and severity of coronary artery disease in
patients presenting with atrial fibrillation according to age.
CAD=Coronary Artery Disease, PCI=Percutaneous Coronary Interven-
tion.
doi:10.1371/journal.pone.0024964.g002
Table 1. Comparison of patients without CAD and patients
with CAD.
Patient characteristic
Without CAD
(n=171)
With CAD
(n=90) P-Value
Age 6 SD (Years) 68610 7368 0.001
Male sex 102 [60%] 65 [72%] 0.057
Type of AF
Paroxysmal 77 [45%] 47 [52%] 0.30
Persistent 47 [27%] 16 [18%] 0.095
Permanent 47 [27%] 27 [30%] 0.67
Risk factors
Smoking 23 [13%] 23 [26%] 0.017
Hypercholesterolemia 52 [30%] 54 [60%] ,0.001
Hypertension 113 [66%] 65 [72%] 0.33
Obesity 38 [22%] 20 [22%] 1.0
Familiar history of CAD 16 [9%] 9 [10%] 0.83
Diabetes mellitus 25 [15%] 21 [23%] 0.11
Left ventricular systolic function*
EF$55% 119 [70%] 52 [58%] 0.075
EF 45–54% 34 [20%] 22 [24%] 0.43
EF 30–44% 12 [7%] 11 [12%] 0.17
EF,30% 6 [4%] 5 [6%] 0.52
Other data
Angina pectoris 3 [2%] 33 [37%] ,0.001
Above-average alcohol consumption 5 [3%] 2 [2%] 1.0
Hyperthyreosis 14 [8%] 14 [16%] 0.091
Medication at discharge
Aspirin 24 [14%] 47 [52%] ,0.001
Clopidogrel 3 [2%] 39 [43%] ,0.001
Phenprocoumon 119 [70%] 32 [36%] ,0.001
Beta-blockers 118 [69%] 62 [69%] 1.0
Calcium channel antagonists 26 [15%] 17 [19%] 0.48
Digitalis glycosides 71 [42%] 44 [49%] 0.29
Amiodarone 7 [4%] 2 [2%] 0.72
Flecainide 23 [13%] 5 [6%] 0.059
Propafenone 16 [9%] 1 [1%] 0.008
AF=Atrial Fibrillation; CAD=Coronary Artery Disease; EF=Ejection Fraction;
SD=Standard Deviation;
*Significant ‘‘within-group’’ trend towards EF$55%.
doi:10.1371/journal.pone.0024964.t001
AF, CAD and Specific Antiarrhythmic Therapy
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patients undergoing coronary artery bypass graft (CABG) were
noted.
Statistical analysis
For normally distributed data the unpaired Student’s t test was
applied. The nonparametric Mann-Whitney U test was used when
the data deviated from a Gaussian distribution as tested by the
Kolmogorov-Smirnov test. Comparisons of categorial variables
were carried out by x
2 and Fisher’s exact tests. Data are presented
as mean 6 standard deviation (SD) or number and percentage for
categorical variables. Values of p,0.05 (two-tailed) were consid-
ered statistically significant. The calculations were performed using
SPSS-Software (SPSS-Software GmbH, Mu ¨nchen, Germany) and
InStat (GraphPad Software, San Diego, USA).
Results
Overall, 261 patients with AF and unknown history of CAD
were analysed. In 171 patients (65.5%) CAD was excluded. A
stable CAD was diagnosed in 34 patients (13%) and PCI or CABG
was performed in 56 patients (21%). No patient died, developed a
stroke or a myocardial infarction. Nine patients underwent
inhospital CABG. Among the patients with newly detected
CAD, the percentage of patients undergoing PCI/CABG was
62.2%. Patients with CAD were older (7368 years vs 68610
years, p=0.001), had significantly more frequent hypercholester-
olemia (60% vs 30%, p,0.001), were more frequent smokers (26%
vs 13%, p=0.017) and suffered from angina more often (37% vs
2%, p,0.001). There was a significant linear trend among the
FRS categories in % and the prevalence of CAD and PCI/CABG
(p,0.0001) with more cases of PCI and CAD at elevated FRS
levels. The association between the FRS and % of CAD in AF is
presented in Figure 1. 61 patients (23%) in this study were .70
years old, and of these 25 (41%) presented with a CAD (Figure 2
shows the age-dependent distribution). The incidence of male
gender was higher among patients with detected CAD, but did not
reach statistical significance (72% vs 60%, p=0.057). Therapy
with a class Ic antiarrhythmic drug was initiated in 39 of 171
patients (23%). The comparison of patients with and without CAD
is shown in Table 1; the overall incidence of CAD (in comparison
to previous studies) is depicted in Figure 3.
Comparing patients with stable CAD and patients undergoing
PCI/CABG (Table 2), patients with stable CAD presented more
often with one-vessel disease (79% vs 34%, p,0.0001) and
significantly less frequently with two- and three-vessel disease. In
patients who underwent PCI, CAD was more frequently detected
in the RCA (62% vs 26%, p=0.001). Regarding age, gender and
single cardiac risk factors, no differences were found between
patients with stable CAD and patients undergoing PCI/CABG.
Patients without CAD and patients with stable CAD were
pooled in one group and were compared with patients who
underwent PCI/CABG (Table 3). Patients with PCI were older
(7468 years vs 69610 years, p,0.001), were more frequently
male (77% vs 60%, p=0.028), had hypercholesterolemia more
often (66% vs 34%, p,0.001) and had a significantly increased
incidence of diabetes mellitus (29% vs 15%, p=0.028). Patients
with PCI also suffered from angina more often (41% vs 6%,
p,0.001). The prevalence and management of CAD (drug-treated
stable CAD vs. PCI/CABG) according to subtype of atrial
fibrillation did not differ significantly (p=0.79, x
2 test) and is
depicted in Figure 4. No significant differences were found when
the different patient groups (without CAD, stable CAD, PCI) were
compared for LV systolic function, but in all groups there was a
significant ‘‘within-group’’ trend towards ejection fraction (EF)
$55% (Tables 1, 2, and 3). Unsuccessful but also successful
electrical cardioversion were more frequently performed in
patients without CAD than in patients with stable CAD or with
PCI/CABG (p,0.01, Figure 5).
Discussion
This single centre study reports on patients with AF undergoing
first time coronary angiography, presenting data relating to the
incidence and severity of CAD.
Figure 3. Overview of reported incidences of coronary artery disease in patients presenting with atrial fibrillation. AF=Atrial
Fibrillation, CAD=Coronary Artery Disease, PCI=Percutaneous Coronary Intervention.
doi:10.1371/journal.pone.0024964.g003
AF, CAD and Specific Antiarrhythmic Therapy
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The Framingham Heart Study [7] concluded that hypertension
and diabetes are significantly associated with risk for AF. In
addition, two other studies reported that hypertension, diabetes
and obesity were conditions predisposing to AF [5]. Nevertheless,
in the case of diabetes, data are contrasting. Whereas Movahed
et al. [22] reported that diabetes is a strong independent risk factor
for AF, Wilhelmsen et al. found no correlation between diabetes
mellitus and AF [6]. In our study, only the comparison of patients
without CAD or stable CAD versus patients undergoing PCI
yielded a significantly higher incidence of diabetes in the PCI
group (Table 3). Regarding other cardiovascular risk factors,
patients with CAD (compared to patients without CAD) had
significantly more frequent hyperlipidaemia, were more frequent
smokers and were older. Importantly, the CHADS2 score
(Congestive heart failure, Hypertension, Age .75, Diabetes, prior
Stroke -doubled [23,24]) or the refined CHA2DS2-VASc score
(difference to CHADS2: AGE $75 years 2 points, AGE 65–74
years 1 point, Vascular disease [prior MI, peripheral artery disease
or aortic plaque], Sex category) should be applied to enable a
stratification of stroke risk [25]. In conclusion, at least a stress test
is reasonable in AF patients with cardiovascular risk factors and,
citing the guidelines, the presence of AF alone, without other
stigmata of CAD, should prompt the cardiologist to search for
causes of AF other than CAD ([20] page 11).
AF and LV function
Since patients with severe CAD are very likely to have impaired
LV systolic function, heart failure seems more likely to be a cause
of AF. Most of the patients included in this study had an
EF$55%. There was a significant ‘‘within-group’’ trend (patient
groups: without CAD, stable CAD, PCI) towards EF$55% and
no significant difference was found comparing the different patient
groups with each other regarding the incidence of EF,30%, EF
30–44% or EF 45–54% (Tables 1, 2 and 3). In any event, in
patients presenting with persistent signs of impaired LV dysfunc-
tion, coronary angiography and careful consideration about the
underlying heart disease is recommended ([20] page 11). Ischemic
cardiomyopathy, heart failure and neurohumoral activation are
hypothesized to play an important mediating role in the
development of new AF [5,13] and previous studies have
demonstrated the occurrence of AF in congestive heart failure
and in myocardial infarction [26]. We agree with Movahed et al.
[22] that it is possible that coronary microvascular disease with
ischemia (inducing metabolic stress) could be involved in the
development of AF.
AF and CAD
In this study, the overall incidence of patients with CAD was
34%. Lip and Beevers [10] described an incidence of 46% and
stated that CAD is one of the commonest causes of AF in the
western world. Watson et al. investigated 121 outpatients with
pacemakers capable of arrhythmia detection and found an
incidence of CAD of 40% in the patient group with .50% time
in AF [27]. On the other hand, Van Gelder et al. (investigating
only patients with permanent AF) detected an incidence of CAD of
18% [18]. Crijns et al. [8] found an incidence of 24% and another
study focusing on middle-aged (5069 years) asymptomatic
subjects with AF, reported an incidence of 22% [19]. All those
studies focus on different patient groups, whereas in this study,
symptomatic patients with angina were also included, as well as all
types of AF. We found an overall incidence of CAD of 34%, which
is in accordance with the incidence of 38% reported by the
AFFIRM study [9] and the incidence of 30% reported by the
ATHENA trial investigating dronedarone [12] - although this trial
included only patients with paroxysmal or persistent AF. The
incidence of CAD in patients with AF (36.3%) described by Krahn
et al. [11] is also in accordance with our data. Interestingly, Krahn
et al. found the strongest relative risk for AF at the onset of
ischemic heart disease, diminishing over time [11]. For a better
general survey, reported incidences are depicted in Figure 1.
The Framingham study reported that CAD was noted in 25%
of the men who later had AF, but prevalence in the controls was
15%, so data did not reach statistical significance [3]. Importantly,
a few months later additional Framingham data showed that the
combination of AF and CAD adversely affected the prognosis
regarding total mortality and that men with CAD had a
statistically significant doubled risk of developing chronic AF [7].
Table 2. Comparison of patients with stable CAD and
patients undergoing PCI/CABG.
Patient characteristics
Stable CAD
(n=34)
PCI/CABG
(n=56) P-Value
Age 6 SD (Years) 72687 4 68 0.24
Male sex 22 [65%] 43 [77%] 0.23
Risk factors
Smoking 9 [26%] 14 [25%] 1.0
Hypercholesterolemia 17 [50%] 37 [66%] 0.18
Hypertension 22 [65%] 43 [77%] 0.23
Obesity 9 [26%] 11 [20%] 0.6
Familiar history of CAD 4 [12%] 5 [9%] 0.73
Diabetes mellitus 5 [15%] 16 [29%] 0.15
Angina pectoris 10 [29%] 23 [41%] 0.37
Left ventricular systolic function*
EF$55% 19 [56%] 33 [59%] 0.83
EF 45–54% 8 [24%] 17 [30%] 0.63
EF 30–44% 6 [18%] 2 [4%] 0.058
EF,30% 1 [3%] 4 [7%] 0.65
Number of vessel disease
1-vessel disease 27 [79%] 19 [34%] ,0.0001
2-vessel disease 4 [12%] 20 [36%] 0.015
3-vessel disease 3 [9%] 17 [30%] 0.019
Localisation of CAD
{
LAD 23 [68%] 45 [80%] 0.21
LCX 12 [35%] 30 [54%] 0.13
RCA 9 [26%] 35 [62%] 0.001
Target vessel
{
LAD 27 [48%]
LCX 8 [14%]
RCA 12 [21%]
CABG 9 [16%]
AF=Atrial Fibrillation; CAD=Coronary Artery Disease; CABG=Coronary Artery
Bypass Graft; EF=Ejection Fraction; LAD=Left Anterior Descending Artery;
LCX=Left Circumflex Artery; PCI=Percutaneous Coronary Intervention;
RCA=Right Coronary Artery; SD=Standard Deviation;
*Significant ‘‘within-group’’ trend towards EF$55%;
{No statistical significance was found regarding the ‘‘within-group’’ allocation of
LAD, LCX and RCA;
{‘‘Within-group’’ incidence of LAD significantly increased (P=0.042).
doi:10.1371/journal.pone.0024964.t002
AF, CAD and Specific Antiarrhythmic Therapy
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men among the patients with CAD, but data did not reach
statistical significance (72% vs 60%, p=0.057, Table 1). Only in
the comparison of patients with PCI versus patients without CAD
or stable CAD, male gender was significantly more common in the
PCI group (77% vs 60%, p=0.028, Table 3). However, CAD is
commonly associated with AF and maybe this association is
somewhat stronger in males.
AF and need for revascularization
In addition to previous data, our study differentiates between
patients with stable CAD (13%) and patients undergoing PCI
(21%). Previously, AF had already been related to the severity of
infarction [28,29] and described as an independent predictor of
death in patients with left main CAD undergoing primary PCI [30].
The GISSI-3 study [4] analysed 17,944 patients after acute
myocardial infarction and determined an incidence of in-hospital
AFof7.8%.Wilhelmsenetal.[6]diagnosedmyocardialinfarctionin
34.2% of their male patient cohort before or after the diagnosis of
AF. Chest pain during exertion was diagnosed in another 11.8% of
men at baseline, comparable with the incidence of stable CAD
(13%) in our study. Considering these incidences and the data
presented in this study, especially before performing ablation
therapy of AF in patients with palpitations and/or chest pain, CAD
as underlying reason for these symptoms should be considered.
AF and location of stenosis
It is often speculated that atrial ischemia plays an important
pathophysiological role in the genesis of AF. Hence significant
stenosis in the proximal right coronary artery and the circumflex
artery prior to the take-off of the atrial branches should increase
the likelihood of AF in these patients. Previous studies report that
Table 3. Comparison of patients without/stable CAD and patients with PCI or CABG.
Patient characteristics
Without/stable CAD
(n=205)
PCI/CABG
(n=56) P-Value
Age 6 SD (Years) 69610 7468 0.001
Male sex 124 [60%] 43 [77%] 0.028
Type of AF
Paroxysmal 96 [47%] 28 [50%] 0.76
Persistent 54 [26%] 9 [16%] 0.16
Permanent 55 [27%] 19 [34%] 0.32
Risk factors
Smoking 32 [16%] 14 [25%] 0.12
Hypercholesterolemia 69 [34%] 37 [66%] ,0.001
Hypertension 135 [66%] 43 [77%] 0.15
Obesity 47 [23%] 11 [20%] 0.72
Familiar history of CAD 20 [10%] 5 [9%] 1.0
Diabetes mellitus 30 [15%] 16 [29%] 0.028
Left ventricular systolic function*
EF$55% 138 [67%] 33 [59%] 0.27
EF 45–54% 42 [20%] 17 [30%] 0.15
EF 30–44% 18 [9%] 2 [4%] 0.26
EF,30% 7 [3%] 4 [7%] 0.26
Other data
Angina pectoris 13 [6%] 23 [41%] ,0.001
Above-average alcohol consumption 6 [3%] 1 [2%] 1.0
Hyperthyreosis 21 [10%] 7 [12%] 0.63
Medication at discharge
Aspirin 36 [18%] 35 [62%] ,0.001
Clopidogrel 8 [4%] 34 [61%] ,0.001
Phenprocoumon 135 [66%] 16 [29%] ,0.001
Beta-Blockers 136 [66%] 44 [79%] 0.10
Calcium channel antagonists 34 [17%] 9 [16%] 1.0
Digitalis glycosides 87 [42%] 28 [50%] 0.36
Amiodarone 9 [4%] 0 0.21
Flecainide 26 [13%] 2 [4%] 0.053
Propafenone 17 [8%] 0 0.028
AF=Atrial Fibrillation; CAD=Coronary Artery Disease; CABG=Coronary Artery Bypass Graft; EF=Ejection Fraction; SD=Standard Deviation;
*Significant ‘‘within-group’’ trend towards EF$55%.
doi:10.1371/journal.pone.0024964.t003
AF, CAD and Specific Antiarrhythmic Therapy
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artery and/or circumflex branch of the left coronary artery [31].
Further, in only 65% of these patients was coronary stenosis
localized before the take-off of atrial branches [31]. Comparing
these results with our data, in patients with stable CAD no
significant difference in the allocation of coronary artery stenosis
among LAD, LCX and RCA was found. Interestingly, in patients
undergoing PCI, CAD was more frequently detected in the RCA.
AF may present as a consequence of its symptoms [32], but on the
basis of this data no answer can be given whether revascularization
of the RCA might contribute to less frequent episodes of AF. The
precise group of patients in which CAD might be causal for AF
remains unclear and further investigations are needed.
AF and treatment with a class Ic antiarrhythmic drug
The data of the present study also have some implications for
the selection of patients for treatment with flecainide and
propafenone. The current AHA/ACC guidelines for the manage-
ment of patients with AF recommend flecainide and propafenone
for a single oral bolus dose (class IIa, ‘‘pill-in-the-pocket’’ concept),
stating that these drugs should not be used in patients with CAD
[20]. The incidence of ‘‘lone AF’’ in patients with persistent AF is
20–25% [33] and CAD should be taken into account as an
underlying heart disease important for the consideration of
ablation therapy ([20] Fig. 12) and the choice of the antiarrhyth-
mic drug ([20] Fig. 11). At least a stress test is reasonable in
patients with signs or risk factors for CAD before administering an
antiarrhythmic agent [20], considering that recurrent or chronic
ischemia can also lead to impaired left ventricular conduction and
thereby cause proarrhythmic effects of class IC antiarrhythmic
drugs. Our data underline this recommendation and importantly
provide data regarding the incidence of patients with AF
undergoing PCI (21%) – a patient group which was identified as
‘‘high-thromboembolic-risk’’, even having a CHADS2#1 [34].
The results of the present study may give rise to further
investigations, which are needed to elucidate the exact incidence
and pathophysiological role of CAD in patients with AF.
Limitations
First, the non-randomized design of this single centre investi-
gation might have potentially influenced the comparative analysis.
Second, similar to previous studies, the results of this study are
limited to hospitalized subjects. While caution is therefore needed
in the interpretation of our data, we consider it improbable that
these limitations have influenced our main findings.
Conclusions
In patients with AF presenting without previously diagnosed or
excluded CAD, the overall incidence of CAD was relatively high
at 34%. The incidence of patients undergoing PCI was 21% and
the incidence of CAD in patients .70 years was even 41%.
Increasing incidence of CRF in the western world should lead to a
careful investigation respecting the FRS in patients presenting with
AF to either definitely exclude or establish an early diagnosis of
CAD. This could contribute to an early and safe therapeutic
strategy considering the initiation of type Ic antiarrhythmics and
oral anticoagulation.
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